Skip to content
Malta's world news feed Local perspective with global outlook
CDE.NEWS The Dispatch

Risks of use of cannabis medicine to treat mental health issues outweigh benefits – Study

epa07781735 A Thai researcher produces Cannabidiol (CBD) extracted from marijuana at Rangsit University Medicinal Cannabis Research Center in Bangkok, Thailand, 20 August 2019. Thai government use seized marijuana to produce its first pharmaceutical cannabis oil after legalizing marijuana for medicinal purposes. The first batch of legally cannabis oil doses are ready to be prescribed to the first thousands of registered patients. Thailand became the first government in Southeast Asia region to legalize cannabis for medical use. Doctors and medical experts around the world are now recognizing cannabis for its medical use, for treating many types of cancer, Parkinson disease, epilepsy, muscle weakness, multiple sclerosis, demyelinating disease and diabetes. EPA-EFE/RUNGROJ YONGRIT

The use of cannabis medicines to treat people with depression, anxiety, psychosis or other mental health issues cannot be justified because there is little evidence that they work or are safe, according to a major new study.

A review of evidence from trials conducted over nearly 40 years, published in the journal Lancet Psychiatry, concludes that the risks outweigh the benefits. And yet, say the authors, they are being given to people with mental health problems in Australia, the US and Canada, and demand is likely to grow.

Prof Louisa Degenhardt of the National Drug and Alcohol Research Centre at UNSW Sydney, Australia, lead author of the study, said the findings had important implications in countries where medical use was allowed.

“There is a notable absence of high-quality evidence to properly assess the effectiveness and safety of medicinal cannabinoids compared with placebo, and until evidence from randomised controlled trials is available, clinical guidelines cannot be drawn up around their use in mental health disorders,” she said.

One can access study here

Report from The Guardian